ED Coding & Reimbursement Alert - 2007 Issue 28
INDUSTRY NOTES: Switch To Q Codes For Albuterol, Levalbuterol
Subscribe or sign in to view the full article.
Article Overview
This brief industry note explains a Medicare Part B change involving billing for nebulized albuterol and levalbuterol products, along with related practice workflow considerations for purchased inhalation solutions and beneficiary notice handling. It also includes a short separate news item about a federal fraud sentencing. The content is most relevant to billing staff, coders, and practice managers who follow Medicare updates and outpatient respiratory therapy claims guidance.
Why This Topic Matters
The article highlights a payer update that can affect how practices report and manage medication-related claims for respiratory services, as well as internal charge capture and nonpayment workflow setup. It also signals broader compliance issues that may matter to organizations tracking Medicare policy and fraud-related enforcement news.
What You Will Learn
- Which general Medicare billing area is changing for nebulized respiratory drugs
- How the article frames purchased inhalation solutions in relation to respiratory testing and treatment services
- What operational follow-up the article says practices should consider for nonpayable items and beneficiary notices
- What separate enforcement-related news item is mentioned at the end of the note
Who Should Read This
- Medical coders
- Billing staff
- Practice managers
- Pulmonary clinic staff
- Respiratory therapy billing teams
Codes Discussed
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com